A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trialChiara Sartor, Antonio Curti, Alfonso Piciocchi et al.|Blood|2025Cited by 0